Table 1.
Baseline characteristics of participants with randomization eGFR <30 ml/min per 1.73 m2
| Characteristica | Canagliflozin (n=84) | Placebo (n=90) | Total (n=174) |
|---|---|---|---|
| Age, yr | 64 (10) | 66 (9) | 65 (10) |
| Male, n (%) | 54 (64) | 52 (58) | 106 (61) |
| Race, n (%) | |||
| White | 55 (65) | 59 (66) | 114 (66) |
| Black | 7 (8) | 2 (2) | 9 (5) |
| Asian | 14 (17) | 11 (12) | 25 (14) |
| Otherb | 8 (10) | 18 (20) | 26 (15) |
| Current smoker, n (%) | 9 (11) | 14 (16) | 23 (13) |
| History of hypertension, n (%) | 82 (98) | 89 (99) | 171 (98) |
| History of heart failure, n (%) | 9 (11) | 14 (16) | 23 (13) |
| Duration of diabetes, yr | 17.5 (9.9) | 16.6 (9.3) | 17.0 (9.6) |
| History of cardiovascular disease, n (%) | 41 (49) | 45 (50) | 86 (49) |
| History of amputation, n (%) | 10 (12) | 2 (2) | 12 (7) |
| Body mass index, kg/m2 | 32 (7) | 31 (6) | 32 (6) |
| Systolic BP, mm Hg | 138 (16) | 139 (17) | 139 (16) |
| Diastolic BP, mm Hg | 75 (9) | 76 (11) | 76 (10) |
| HbA1c, % | 8.2 (1.3) | 8.0 (1.1) | 8.1 (1.2) |
| eGFR, ml/min per 1.73 m2 | 26 (3) | 27 (3) | 26 (3) |
| UACR, mg/g, median (IQR) | 1056 (459, 2525) | 1153 (483, 2253) | 1064 (464, 2376) |
HbA1c, glycated hemoglobin; UACR, urinary albumin-creatinine ratio; IQR, interquartile range.
a
Data are mean (SD) unless otherwise indicated.
b
Other includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported.